---
title: "Piramal Pharma Receives FDA Form 483 With VAI Observations at U.S. Plant"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285851562.md"
description: "Piramal Pharma Limited announced that the U.S. FDA conducted a Good Manufacturing Practices inspection at its Sellersville facility, resulting in a Form 483 with three Voluntary Action Indicated observations. The findings did not involve data integrity, and the company plans to respond promptly while collaborating with the regulator. This indicates limited immediate regulatory risk, but highlights the need for ongoing compliance in the pharmaceutical sector to reassure investors and customers about product quality. Piramal Pharma operates globally, focusing on manufacturing pharmaceutical products under stringent standards."
datetime: "2026-05-10T20:52:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285851562.md)
  - [en](https://longbridge.com/en/news/285851562.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285851562.md)
---

# Piramal Pharma Receives FDA Form 483 With VAI Observations at U.S. Plant

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Piramal Pharma Limited ( (IN:PPLPHARMA) ) has issued an announcement.

Piramal Pharma Limited reported that the U.S. FDA conducted a Good Manufacturing Practices inspection at its Sellersville, U.S., facility from May 4 to May 8, 2026, resulting in a Form 483 with three observations classified as Voluntary Action Indicated. None of the findings involved data integrity, and the company plans to submit a detailed response within required timelines while working closely with the regulator to resolve all issues.

The announcement signals that the observations are not considered severe by the inspectors, suggesting limited immediate regulatory risk for the facility’s operations. However, the outcome underscores ongoing regulatory scrutiny in the pharmaceutical sector and highlights Piramal Pharma’s need to maintain robust compliance to protect its U.S. business and reassure investors and customers about product quality and reliability.

**More about Piramal Pharma Limited**

Piramal Pharma Limited is an India-based pharmaceutical company operating globally with a focus on manufacturing and supplying pharmaceutical products and services. The company runs facilities in markets such as the U.S., supporting its position as a producer for regulated markets under stringent quality and compliance standards.

**Average Trading Volume:** 240,166

**Technical Sentiment Signal:** Buy

**Current Market Cap:** 238.9B INR

See more data about PPLPHARMA stock on TipRanks’ Stock Analysis page.

## Related News & Research

- [While Everyone Chases AI, Pharma Keeps Getting Cheaper](https://longbridge.com/en/news/286650835.md)
- [Doceree launches Daily Command, an AI platform for brand teams co-built by pharma leaders](https://longbridge.com/en/news/286583833.md)
- [20:00 ETLOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma](https://longbridge.com/en/news/286687690.md)
- [Strides Pharma Q4FY26 results: Net profit jumps 51% to ₹129 crore](https://longbridge.com/en/news/286757182.md)
- [16:52 ETNexusTek Named a Contender in ISG Provider Lens® Life Sciences Digital Services 2026 Report](https://longbridge.com/en/news/286818120.md)